Pfizer raised $ 3.5bn from sales of the Covid-19 vaccine in the first quarter and raised its full-year earnings expectation from গুলি 15 billion to 26 26 billion as of Tuesday, according to its quarterly earnings report.
The U.S. pharmaceutical company, which has shared profits from its covid vaccine with its development partner Bioentech, has raised its full-year income tax target to 4 41.4 billion, largely due to an agreement signed in 2021 to supply 1.6 billion doses.
Total first-quarter earnings rose 14.6bn, a 45 percent increase over the same period in 2020, beating analysts’ forecast of ৩ 13.7 billion.
Chief executive Albert Bourlala said thin earnings per share had fallen to 86 cents and that vaccine revenue had come from sales in more than 50 countries, according to chief executive Albert Bourlala.
“I can’t be bigger than the way Pfizer started 2021,” Borla said in a prepared comment. “We continued the pace of production and shipment of our Covid-19 vaccine – in many cases exceeding our contractual obligations for delivery times.”
As of May 3, 430 million doses of the covid vaccine have been shipped to 91 countries. Pfizer plans to apply for full FDA approval of its coronavirus vaccine by the end of May, and U.S. regulators Expected To allow its use among adolescents aged 12-15 in the coming days.
Borla said he expects “sustainable demand” for the Covid-19 vaccine, like the flu vaccine. He said test data for the first-identified alternative vaccine in South Africa is expected in early July.
Data was submitted to the FDA on Friday to show that the mRNA vaccine can be stored in a refrigerator for up to 4 weeks, making it easier for vaccination sites to shake without a freezer, Borela added.
The company is also working on creating a new formula that can store up to 10 weeks in a refrigerator. Data on the new formation is expected in August.
Shares of Pfeiffer rose 1.6 percent in pre-market trading on Tuesday.